Solid Tumors
37 competing products in clinical development for Solid Tumors.
Pipeline by Phase
Phase 132
Phase 1/21
Phase 24
All Products (37)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| S-531011 + Pembrolizumab + Bevacizumab | Shionogi | Phase 1/2 | Recruiting | 39 |
| AUBE00 + Cetuximab | Chugai Pharmaceutical | Phase 1 | Recruiting | 36 |
| DS3610a | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| DS-2243a | Daiichi Sankyo | Phase 1 | Recruiting | 36 |
| VRT106 | Sun Pharmaceutical | Phase 1 | Recruiting | 36 |
| IMAB362 | Astellas Pharma | Phase 2 | Completed | 35 |
| E7080 + Comparator Drug + Comparator Drug: Sorafenib | Eisai | Phase 2 | Completed | 35 |
| Regorafenib, (Stivarga, BAY73-4506) + Nivolumab (Opdivo) | Ono Pharmaceutical | Phase 2 | Completed | 35 |
| mRNA-4157 + Pembrolizumab + SoC Treatment | Merck | Phase 1 | Active | 33 |
| E7050 | Eisai | Phase 1 | Completed | 29 |
| LY2875358 + Erlotinib + Gefitinib | Eli Lilly | Phase 1 | Completed | 29 |
| ERY974 | Chugai Pharmaceutical | Phase 1 | Completed | 29 |
| Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oral | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Compound AC220 | Daiichi Sankyo | Phase 1 | Completed | 29 |
| patritumab | Daiichi Sankyo | Phase 1 | Completed | 29 |
| tivantinib + omeprazole + s-warfarin + caffeine + digoxin + midazolam | Daiichi Sankyo | Phase 1 | Completed | 29 |
| PLX3397 + Paclitaxel | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Tivantinib + Placebo | Daiichi Sankyo | Phase 1 | Completed | 29 |
| DS-8895a | Daiichi Sankyo | Phase 1 | Completed | 29 |
| Claudiximab | Astellas Pharma | Phase 1 | Completed | 29 |
| ASP5878 | Astellas Pharma | Phase 1 | Completed | 29 |
| E7130 + E7130 | Eisai | Phase 1 | Completed | 29 |
| TBI-1201 + Cyclophosphamide + Fludarabine | Shionogi | Phase 1 | Completed | 29 |
| S-3304 | Shionogi | Phase 1 | Completed | 29 |
| lenvatinib + pembrolizumab | Eisai | Phase 1 | Completed | 29 |
| Eribulin-LF | Eisai | Phase 1 | Completed | 29 |
| Panitumumab | Amgen | Phase 1 | Completed | 29 |
| Farletuzumab Ecteribulin | Eisai | Phase 1 | Completed | 29 |
| LY2523355 | Kyowa Kirin | Phase 1 | Completed | 29 |
| KRN951 | Kyowa Kirin | Phase 1 | Completed | 29 |
| Tomivosertib (eFT-508) | eFFECTOR Therapeutics | Phase 2 | Completed | 25 |
| TBI-1301 + Cyclophosphamide + Fludarabine | Shionogi | Phase 1 | UNKNOWN | 25 |
| DS-2248 | Daiichi Sankyo | Phase 1 | Terminated | 21 |
| CS-7017 and Bexarotene | Daiichi Sankyo | Phase 1 | Terminated | 21 |
| M3541 | Merck | Phase 1 | Terminated | 21 |
| AC480IV + Docetaxel | Daiichi Sankyo | Phase 1 | Withdrawn | 21 |
| E7016 + TMZ | Eisai | Phase 1 | Terminated | 21 |